Could a vaccine finally stop the 'Kissing Disease'?
NCT ID NCT05683834
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tested a new vaccine designed to prevent Epstein-Barr virus (EBV) infection, which causes most cases of infectious mononucleosis (mono). Twenty-five healthy adults aged 18 to 25 who had never been infected with EBV received either the vaccine or a placebo. The goal was to see if the vaccine is safe and triggers an immune response that could protect against EBV.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
EBV gp350-Ferritin vaccine with Matrix-M1 adjuvant
What this could lead to
If successful, this could lead to a vaccine that prevents Epstein-Barr virus infection and the fatigue and complications of mono.
What could go wrong
This is an early-phase trial with only 25 participants, so results may not apply to everyone. The vaccine may not provide strong or lasting protection.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for EPSTEIN BARR VIRUS INFECTION are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
National Institutes of Health Clinical Center
Bethesda, Maryland, 20892, United States
-
University of Minnesota
Minneapolis, Minnesota, 55455, United States